Michael Burnet
Managing Director
Microbiology
Biotech Umea
Sweden
Biography
Michael Burnet, Ph.D., Managing Director, Oncology Discovery, Synovo GmbH Michael Burnet studied at the Universities of Melbourne and Adelaide (Ph.D.) prior to postdoctoral work in Canada, the U.S., and France focusing on biochemistry of oxygenases. He was then a discovery project manager at Zeneca in the United Kingdom involved in Hit-to-Lead characterization. He founded Synovo GmbH in Tubingen, Germany in 2004, and has since added 4 other self-sustaining enterprises. Synovo is a drug discovery and services company with a focus on in vivo disease models. In 2008, Synovo discovered a novel series of potent micro-environment modulators that modulate the cytokine patterns of tumours and notably that of the myeloid infiltrate. These substances synergize both checkpoint and other antibody therapies. The series has since received orphan designation for pancreas cancer. Michael’s research focus is mechanisms of improved immunotherapy in oncology.
Research Interest
microbiology
